EVMN Kyle Carver bought Evommune, Inc. shares — SEC Form 4BUYEvommune, Inc.

The stock is currently trading at $13.49, up 4.17% over the last five days but down 34.16% over the past month. It remains 59.37% below its 52-week high of $33.20.

• •Phase IIb Urticaria Study Misses Primary Goal on June 30, 2026, halting EVO756 development for CSU.
• •Termination of oral drug development in CSU on June 29, 2026, shifting focus to AD and migraine trials.
• •CFO Kyle Carver executed the largest purchase of his career on July 8, 2026.

• •The stock faces significant short-term pressure with a short interest of 17.61% of the float.
• •The company reported a failed Phase IIb trial on June 30, 2026, which halted development of its lead drug candidate.